Environment
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
StateArizonaEnacted
SB 1188: approved medications; scheduling; prescription authority
T.J. Shope
SB 1188 status: Enacted — Signed by Governor (updated Jun 22, 2026).
Source
LegiScan
Confidence
High
Analysis basis
LegiScan full bill text
01
What this bill does
Official summary alongside an AI-generated read on where it stands and why.
Overall Score
71OUT OF 100
Score:71/100 civic fit
Risk:Low Risk
Impact:Moderate Impact 60/100
Constitutionality90%
Bipartisan85%
Public opinion75%
Bill summary
What changes
The bill requires Arizona's controlled substance scheduling to automatically mirror any scheduling or rescheduling action taken by the federal DEA for FDA-approved substances.
Who is affected
The Arizona State Board of Pharmacy, healthcare providers, pharmacies, and patients in Arizona.
Requirements and enforcement
The Board of Pharmacy must treat federally scheduled substances as identically scheduled under state law, effective immediately upon the federal change.
Costs and funding
Negligible administrative costs; likely a reduction in operational costs due to the elimination of routine scheduling hearings.
When it takes effect
Effective upon signature by the Governor, which occurred on June 22, 2026.
Potential benefits
Ensures timely and consistent patient access to FDA-approved medicines; reduces administrative red tape for the state pharmacy board; harmonizes state and federal regulatory frameworks.
Risks and tradeoffs
The loss of state-level discretion; the state effectively abdicates its ability to independently review or modify scheduling decisions to match specific state conditions.
What is still unknown
The long-term impact on the state's ability to maintain unique controlled substance protections if federal policies become misaligned with Arizona public health interests.
02
Impact analysis
✦ AI analysisModeled effects across six domains, estimated from bill text and comparable legislation.
Economy
Positive outlook
75%
Benefits
- Reduced administrative burden on the state pharmacy board
- Faster regulatory alignment for new medical products
- Consistent regulatory landscape for pharmaceutical providers
Risks
- Loss of state-level board control over local scheduling
- Compliance adjustment costs for pharmacy record systems
- Shift of authority removes state-specific market considerations
Society
Positive outlook
70%
Benefits
- Increased patient access to modern medications
- Streamlined availability of FDA-approved drugs
- Consistency with national healthcare delivery standards
Risks
- Reduced local oversight of specific substance availability
- Limited public comment period for scheduling changes
- Risk of automatic adoption of restrictive federal policies
Technology Industry
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
Civic Accountability
Positive outlook
65%
Benefits
- Establishes a transparent, bright-line rule for scheduling
- Reduces potential for political interference in scheduling
- Ensures state law reflects current federal scientific review
Risks
- Abdication of state-level regulatory oversight to the DEA
- Lack of state-level agency discretion in scheduling
- Reduced transparency into specific state-level review processes
Public Health & Safety
Positive outlook
75%
Benefits
- Faster adoption of necessary life-saving treatments
- Standardized safety profiles for controlled substances
- Timely availability of recent FDA medical innovations
Risks
- Risks of automated adoption of federal scheduling failures
- Reduced ability to adapt to state-specific health crises
- Rapid shifts in status may complicate clinical practices
03
How trustworthy & consequential it is
Sourcing already shown above, this is what the analysis found worth flagging.
Source
LegiScan
Official bill text or data from LegiScan.
Confidence
High
Information is complete and verified.
Analysis basis
LegiScan full bill text
Source used for this bill's analysis.
Source note
The primary risk is the loss of state-level regulatory discretion should federal scheduling actions prove unsuitable for Arizona's specific public health needs.
Analysis scope
The analysis relies on the provided statute text which focuses on administrative scheduling authority.
04
Where it stands
Official recordSigned by Governor
- IntroducedComplete
- CommitteeComplete
- Chamber votesComplete
- Final agreementComplete
- GovernorComplete
- EnactedComplete
05
How it affects your district
✦ Personalized
Set your location
Add your district to see how this bill may affect your community and who to contact.
Your Representatives
Your representatives appear here once you add your location.
06
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.